TruthArchive.ai - Related Video Feed

The speaker asks if the Pfizer COVID vaccine was tested for its ability to stop virus transmission before being released. They request a clear yes or no answer and the data to be shared with the committee. The response states that they did not have prior knowledge of stopping transmission before the vaccine entered the market and had to rely on scientific research. Another speaker expresses outrage, claiming that people were pressured to get vaccinated based on the false belief that it would protect others.

Speaker 0 asked for the impossible: to develop a vaccine in 8 months instead of 10 years without cutting corners. They emphasized safety. Speaker 1 questioned Pfizer's transparency in mutating COVID viruses. Speaker 0 stressed the importance of vaccination for public health. Pfizer's CEO discussed vaccine production and effectiveness. They thanked the US government for support. The CEO highlighted the vaccine's 95.6% efficacy. The conversation ended with a call for public vaccination.

The speaker asked if the Pfizer COVID vaccine was tested for stopping virus transmission before it was released. They wanted a clear yes or no answer and requested the data to be shared with the committee. In response, it was stated that no, they did not have knowledge about stopping transmission before the vaccine entered the market. They had to act quickly.

The discussion revolves around the efficacy and safety of COVID-19 vaccines, particularly in relation to transmission, myocarditis rates, and the influence of pharmaceutical companies. The speakers debate whether vaccines reduce transmission and the risks associated with myocarditis. They also question the motives of pharmaceutical companies and their impact on public health. Ultimately, they express differing views on the role of vaccines in preventing illness and the influence of pharmaceutical companies. Translation: The conversation focuses on COVID-19 vaccine effectiveness, safety, transmission, and myocarditis risks, as well as the pharmaceutical industry's influence on public health. Speakers debate vaccine impact on transmission and myocarditis rates, and discuss pharmaceutical companies' motives and health outcomes. They share conflicting opinions on vaccines' ability to prevent illness and the pharmaceutical industry's role.

The White House blames a few bad actors for spreading online misinformation that is causing harm. It is important to get vaccinated not only for personal protection but also to safeguard society. A member of the European Parliament from the Netherlands recently had a viral exchange with a Pfizer executive regarding whether the vaccine was tested for stopping virus transmission before being released. The executive clarified that the vaccines were extensively tested in clinical trials, but their specific effectiveness in stopping transmission was not known prior to market entry.

Speaker 0 questions understanding of vaccine causing myocarditis, mentioning Pfizer's awareness. Speaker 1 doubts if vaccine was tested for stopping transmission before market release. Speaker 0 believes vaccination was optional, not forced.

Thank you, Senator Canavan. Did Pfizer test if the COVID-19 vaccine could stop or reduce virus transmission before its late 2020 approval? To bring the vaccine to patients, we needed to show it was safe and effective in preventing illness, severe disease, and hospitalizations. The primary goal was to protect the vaccinated individual. I appreciate that, but my question remains unanswered. On December 3, 2020, your CEO stated that it was uncertain if vaccinated individuals could carry and spread the virus. Was he correct that Pfizer did not know if the vaccine could reduce transmission? We designed our clinical programs with regulatory agencies to demonstrate the vaccine's safety and effectiveness in preventing infections. Okay, let’s move on.

A year ago, the speaker requested data from Emma, including all clinical trials done by medical companies before they requested marketing authorization for the green certificate. Regarding Pfizer, the speaker notes the company submitted a clinical trial that started on January 14, 2020. The speaker questioned a Pfizer representative about how tests for the vaccine began so soon after the December 2019 emergence of COVID-19, but the representative declined to answer. The speaker also asked the CEO of Moderna how they submitted trials since 2017, years before the virus was discovered in the winter of 2019. The speaker states that the CEO of Moderna did not answer how this was possible. The speaker says these are legitimate questions that people are asking, but unfortunately, the companies are declining to answer.

The Office of Gene Technology Regulator is questioned about gene therapies and the mRNA vaccines. The speaker presents evidence from Pfizer's website, the American Society of Gene and Cell Therapy, and the TGA's non-clinical report to support the claim that mRNA vaccines are gene therapy. The regulator deflects responsibility for testing genotoxicity and manufacturing processes conducted in other countries. The speaker highlights the contradiction in the regulator's statements and the disagreement with Pfizer's definition of gene therapy. The regulator argues that the definition of gene therapy is subjective. The conversation ends without a resolution.

The speaker questions whether the mRNA complexes in the vaccines meet the definition of genetically modified organisms (GMOs) under Australian legislation. The response states that mRNA technology is not gene therapy and does not alter human DNA. The speaker insists on knowing if the possibility was examined, but the response reiterates that the vaccines are not GMOs. The speaker then asks if Pfizer has notified its underwriters about potential litigation, but the response is uncertain and requests further investigation. Another speaker presents a document from Pfizer's website stating that gene technology includes a process used in the COVID vaccine. The committee agrees to review the document and suggests sending additional questions to Pfizer.

Pfizer was asked if they tested whether their COVID-19 vaccine could reduce or stop the transmission of the virus before its approval. The Pfizer representative stated that the primary purpose of the vaccine was to protect the person who received it and prevent illness, severe disease, and hospitalizations. The senator then referred to a statement made by Pfizer's CEO on December 3, 2020, where he mentioned uncertainty about the vaccine's ability to reduce transmission. The Pfizer representative reiterated that their clinical programs were designed to demonstrate the vaccine's safety and effectiveness in preventing infections. Due to time constraints, the senator moved on without a definitive answer.

The speakers discuss the importance of vaccination in reducing transmission and returning to normalcy. They express confidence in the vaccines' ability to prevent illness and transmission. They emphasize the need for people to get vaccinated for their own protection and to break the chain of transmission. Vaccinated individuals are seen as dead ends for the virus, preventing further spread. However, it is mentioned that initial data on vaccine effectiveness against transmission was limited at the time of emergency use authorization. A question is raised about whether the Pfizer vaccine was tested for transmission prevention before its release, to which the response is that they had to move quickly based on scientific progress.

Speaker 0 acknowledges reports of myocarditis and pericarditis associated with the Pfizer vaccine but seems unsure about the mechanism behind it. Speaker 1 asks if the vaccine was tested for its ability to stop virus transmission before being released. Speaker 2 questions if people were forced to get vaccinated to keep their jobs and asks Speaker 0 to retract their statement. Speaker 0 clarifies that everyone had the choice to get vaccinated or not, and they don't believe anyone was forced.

The speaker claims that the genetic COVID-19 injections are more harmful than beneficial, especially for young and healthy individuals. They argue that the vaccines do not reduce COVID-19 infection and can actually increase the risk of infection, disease, and death. The speaker also mentions potential damage to the heart, brain, reproductive tissue, lungs, and immune system. Another speaker questions the testing of the Pfizer COVID vaccine and demands data from the committee. The response states that the vaccine was not tested for stopping transmission before entering the market. There are also concerns raised about the vaccines causing harm to women of reproductive age and unborn babies. The transcript concludes with accusations of fraud and illegal advertising, suggesting that the vaccines have not been presented with their associated risks.

A recent study suggests that Pfizer may have excluded known deaths in the vaccine arm of its clinical trial from its data filing with the FDA in 2020. The study also found that trial subjects vaccinated with Pfizer's COVID-19 vaccine experienced a significant increase in cardiovascular deaths compared to placebo controls. This information was not disclosed by Pfizer when the FDA was evaluating the vaccine for emergency use. Additionally, researchers identified instances where Pfizer attributed potential vaccine-associated deaths to other causes, undermining vaccine safety data. The data presented to the FDA prior to the authorization of Pfizer's vaccine did not include all the deaths that occurred during the trial. The speaker raises concerns about the prioritization of profit over lives and warns against trusting Big Pharma.

Pfizer marketed its vaccine as safe for pregnant women, but reports showed adverse events and miscarriages. They denied a link between their vaccine and heart conditions, despite evidence. Pfizer claimed effectiveness against variants, but data showed otherwise. They also misled about transmission and censored criticism on social media. Pfizer avoided government oversight in vaccine development. Despite these issues, Pfizer successfully marketed their vaccine in Kansas. Multiple states are filing suits against Pfizer.

The Pfizer COVID vaccine was not tested for its ability to stop the transmission of the virus before it entered the market. The speaker acknowledges that they had to work quickly to understand the situation and move at the speed of science.

The speaker cross-examined Dr. Lourenco about the safety of the COVID-19 vaccine. They compared it to previous vaccines like pneumonia and shingles, asking if the same rigorous testing process was followed. Dr. Lourenco confirmed that animal trials and two phases of human trials were conducted for those vaccines before approval. However, she admitted that the final phase of human trials, which has been completed for all other vaccines in Canada, was not done for the COVID-19 vaccines. She tried to justify this by mentioning a new process.

Speaker 0 questions Speaker 1 about a report stating that serious adverse reactions occur in 1 in 800 vaccinated individuals. Speaker 1 claims to be unaware of the report but mentions routine screening of literature for adverse events. When asked about Moderna's rate of serious adverse events, Speaker 1 cannot provide the information. Speaker 0 expresses frustration and finds it extraordinary that a multinational company cannot provide this data. Speaker 1 offers to provide the information later but states that no safety concerns were observed in their clinical trials. Speaker 0 concludes that the conversation is a waste of time.

The speaker asked if the Pfizer COVID vaccine was tested for stopping virus transmission before it was released. They requested a clear yes or no answer and asked for the data to be shared with the committee. The speaker then stated that they did not have knowledge about stopping immunization before the vaccine entered the market.

Pfizer's claim of 96% efficacy for their vaccine was questioned. The study and data were not independently verified, and Pfizer wanted to keep the data hidden for 75 years. The true effectiveness of the vaccine, based on absolute risk reduction, is less than 1%. More people died and were harmed in their trials compared to the placebo group. The vaccine's safety was questionable from the start, and it is not effective. Additionally, appropriate studies were not conducted for new variants.

Pfizer is being sued for defrauding the government, but they claim they did not commit fraud. They argue they provided what the government requested, even if it was a faulty product distributed worldwide. This information is crucial and not widely known.

A year ago, the speaker requested data from Emma, including clinical trials from medical companies before they sought marketing authorization for their products. Regarding Pfizer, the speaker notes that the company submitted a clinical trial that started on January 14, 2020. The speaker questioned a Pfizer representative about how Pfizer started testing a vaccine in January 2020, just days after the Chinese government released DNA data about the virus in December 2019, but the representative declined to answer. The speaker also mentions that Moderna submitted trials dating back to 2017. The speaker asked the CEO of Moderna how it was possible to submit vaccine tests years before the virus was discovered in December 2019. The speaker states that these are legitimate questions that people are asking, but unfortunately, the companies are declining to answer.

Speaker 0 questions Speaker 1 about the lack of clinical trial data for the MMR vaccine. Speaker 1 insists that the vaccine was extensively tested before being licensed and that millions of doses have been used. Speaker 0 asks for proof of pre-licensure clinical trials, but Speaker 1 only refers to a book and mentions studies done in the 1960s. Speaker 0 argues that the data provided is not sufficient and questions the absence of a placebo group. Speaker 1 admits uncertainty about the inclusion of control groups but maintains that safety assessments were conducted. Speaker 0 concludes that no randomized placebo-controlled study exists for the MMR vaccine. Speaker 1 agrees to provide additional information after the deposition.

Pfizer has been forced to release previously secret documents, including FDA approval packages, due to court orders and successful FOIA requests. These documents reveal that Pfizer tested different versions of their vaccine during preclinical and clinical trials, which goes against FDA guidance. The different versions included modified RNA, unmodified RNA, self-amplifying RNA, and Spike protein alone. Surprisingly, all these versions were tested under the same investigational new drug number, despite FDA guidance stating that multiple versions should have their own individual numbers. Additionally, the toxicity of the mRNA active ingredient in the COVID-19 vaccines was never studied. This raises concerns about the regulatory process and the lack of safety testing.